Modulation of heart function by Muscle LIM protein-mediated mechanotransduction
肌肉 LIM 蛋白介导的机械转导调节心脏功能
基本信息
- 批准号:10645223
- 负责人:
- 金额:$ 41.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:3 year oldActinsActomyosinAffectAffinityAutophagocytosisBiomechanicsBiopsyBioreactorsCalcineurinCalcineurin inhibitorCalciumCalpainCardiacCardiac MyocytesCardiac MyosinsComplexComputer ModelsCoupledDevelopmentDiastoleDisinhibitionEventExtracellular MatrixFamilial Hypertrophic CardiomyopathyFiberFibroblastsFoundationsFutureGenerationsGenesGeneticHeart DiseasesHeart HypertrophyHeart failureHeterozygoteHumanHyperactivityHypertrophic CardiomyopathyHypertrophyImpairmentIndividualInheritedInterventionInvestigationLasersLeftLeft Ventricular HypertrophyLengthLysosomesMechanicsMediatingMicrofilamentsMolecularMuscleMuscle ContractionMutationMyocardial dysfunctionMyocardiumMyosin ATPaseMyosin Heavy ChainsNonsense CodonNuclearObstructionPPP3CA geneParentsPathologicPathway interactionsPatientsPeptide HydrolasesPersonsPhenotypePhysiologicalPoint MutationProductionProtein IsoformsProteinsRelaxationRepressionRodentRoleSarcomeresSignal TransductionSkinSomatic CellStem Cell FactorStressStretchingSystemSystoleT-Cell ActivationTestingTissuesUbiquitinVentricularbeta-Myosincardiac tissue engineeringdesigndisease phenotypeheart functionhuman diseaseimprovedinduced pluripotent stem cellinduced pluripotent stem cell derived cardiomyocytesinnovationinsightmalemechanical propertiesmechanical stimulusmechanotransductionmouse modelmulticatalytic endopeptidase complexmuscle LIM proteinmutantnovelnovel strategiesnovel therapeuticsnuclear factors of activated T-cellspharmacologicpreventprobandprotein degradationrecruitresponsescaffoldsudden cardiac deathtransmission process
项目摘要
Familial hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and is typically caused
by mutations in genes encoding sarcomeric proteins that regulate cardiac contractility. HCM manifestations include
left ventricular hypertrophy and heart failure, arrythmias, and sudden cardiac death. The mechanotransduction
mechanism by which dysregulated sarcomeric force production is sensed and leads to pathological remodeling
remains poorly understood in HCM, thereby inhibiting the efficient development of new therapeutics. Our discovery
was based on insights from a severe phenotype of an individual with HCM and a second genetic alteration in a
sarcomeric mechano-sensing protein. We effectively derived cardiomyocytes from patient-specific induced
pluripotent stem cells (iPSC-CMs) and developed robust engineered heart tissues (EHTs) by seeding iPSC-CMs into
a laser-cut scaffold possessing native cardiac fiber alignment, for studying human cardiac mechanobiology at both
cellular and tissue levels. Coupled with computational modeling for muscle contraction and rescue of disease
phenotype via gene editing and pharmacological interventions, we have identified a new mechanotransduction
pathway in HCM. Enhanced actomyosin crossbridge formation caused by sarcomeric mutations in cardiac myosin
heavy chain (MYH7) led to increased force generation, which when coupled with slower twitch relaxation,
destabilized the muscle LIM protein (MLP) stretch-sensing complex at the Z-disc. Subsequent reduction in the
sarcomeric MLP level caused disinhibition of calcineurin–nuclear factor of activated T-cells (NFAT) signaling,
which promoted cardiac hypertrophy. By mitigating enhanced actomyosin crossbridge formation through either
genetic or pharmacological means, we alleviated stress at the Z-disc, preventing the development of hypertrophy
associated with sarcomeric mutations. This proposal will dissect the roles of systolic and diastolic Z-disc stress
in modulating the MLP mechanosensory complex and elucidate the molecular mechanisms that mediate the
repression of calcineurin/NFAT by MLP as well as MLP protein degradation by stretch-sensing. We have recently
developed a new bioreactor that can expose EHTs to precisely prescribed afterloads, so we can test the
hypothesis that higher systolic forces produced by crossbridges under higher afterloads destabilize MLP at the
Z-disc and activate hypertrophic signaling during systole. Additionally, EHTs will be subjected to culture under
conditions of either constant length or diastolic stretch to mimic ventricular filling. After repeated stretching, EHTs
will be examined for hypertrophic signaling. We will unravel mechanistic insights into how saromeric MLP is
degraded in response to Z-disc stress. In addition, we will dissect molecular mechanisms by which MLP inhibits
calcineurin/NFAT hypertrophic responses in systole and diastole. Elucidation of the molecular mechanisms of a
common sarcomeric contraction/MLP/calcineurin mechanotransduction pathway will help to design novel
strategies for a wide spectrum of heart failure patients potentially through stabilizing the Z-disk MLP mechanosensory
complex.
家族性肥厚型心肌病(HCM)是最常见的遗传性心脏病,通常由
通过编码肌节蛋白的基因突变来调节心脏收缩能力。HCM的表现包括
左心室肥厚和心力衰竭、心律失常和心脏性猝死。机械转导
感知肌节作用力异常并导致病理性重塑的机制
在肥厚型心肌病中仍然知之甚少,从而抑制了新疗法的有效开发。我们的发现
是基于对一名肥厚型心肌炎患者的严重表型和第二次基因改变的洞察
肌节机械感应蛋白。我们有效地从患者特异性诱导的心肌细胞中获得了
多能干细胞(IPSC-CMS)和通过种植IPSC-CMS发展成强大的工程心脏组织(EHTS
一种具有天然心脏纤维排列的激光切割支架,用于研究人体心脏机械生物学
细胞和组织水平。与肌肉收缩和疾病救援的计算建模相结合
通过基因编辑和药物干预,我们已经确定了一种新的机械转导
HCM中的通路。肌球蛋白肌瘤突变引起的肌动球蛋白交叉桥形成增强
重链(MYH7)导致了更多的力量产生,当再加上较慢的抽搐放松时,
破坏了Z盘处的肌肉LIM蛋白(MLP)拉伸传感复合体的稳定性。随后减少了
肌瘤MLP水平可解除钙调神经磷酸酶激活T细胞核因子(NFAT)信号的抑制,
促进了心肌肥大。通过以下两种途径之一减轻肌动球蛋白交叉桥的形成
通过遗传或药物手段,我们缓解了Z盘应力,防止了肥大的发展
与肉瘤突变有关。这项建议将剖析收缩和舒张期Z盘应力的作用
在调节MLP机械感觉复合体方面并阐明介导MLP的分子机制
MLP对钙调神经磷酸酶/NFAT的抑制以及拉伸传感对MLP蛋白的降解。我们最近做了
开发了一种新的生物反应器,可以将EHTS暴露在精确的规定后负载中,所以我们可以测试
假设在较高的后载下,交叉桥产生的较高的收缩力会破坏MLP在
Z-Disc和激活收缩期间的肥大信号。此外,EHTS将在以下条件下接受文化
恒定长度或舒张期拉伸以模拟脑室充盈的状态。经过反复拉伸,EHTS
将接受肥大信号检查。我们将揭开MLP的机械性洞察力
在Z-Disc压力下退化。此外,我们还将剖析MLP抑制的分子机制
钙调神经磷酸酶/NFAT在收缩和舒张期的肥大反应。A的分子机制的阐明
常见的肌节收缩/MLP/钙调神经磷酸酶机械转导通路将有助于设计新的
通过稳定Z-Disk MLP机械感觉对广泛心力衰竭患者的潜在策略
很复杂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yibing Qyang其他文献
Yibing Qyang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yibing Qyang', 18)}}的其他基金
Modulation of heart function by Muscle LIM protein-mediated mechanotransduction
肌肉 LIM 蛋白介导的机械转导调节心脏功能
- 批准号:
10503955 - 财政年份:2022
- 资助金额:
$ 41.88万 - 项目类别:
Development of HLA engineered universal vascular grafts from human iPSCs
利用人类 iPSC 开发 HLA 工程通用血管移植物
- 批准号:
10457467 - 财政年份:2021
- 资助金额:
$ 41.88万 - 项目类别:
Development of HLA engineered universal vascular grafts from human iPSCs
利用人类 iPSC 开发 HLA 工程通用血管移植物
- 批准号:
10685550 - 财政年份:2021
- 资助金额:
$ 41.88万 - 项目类别:
Development of HLA engineered universal vascular grafts from human iPSCs
利用人类 iPSC 开发 HLA 工程通用血管移植物
- 批准号:
10298018 - 财政年份:2021
- 资助金额:
$ 41.88万 - 项目类别:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
用于紧急手术护理的现成干细胞血管移植物
- 批准号:
10841794 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
用于紧急手术护理的现成干细胞血管移植物
- 批准号:
10622873 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
用于紧急手术护理的现成干细胞血管移植物
- 批准号:
10414459 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
用于紧急手术护理的现成干细胞血管移植物
- 批准号:
10636647 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
用于紧急手术护理的现成干细胞血管移植物
- 批准号:
10439796 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Readily Available Stem Cell-Based Vascular Grafts for Emergent Surgical Care
用于紧急手术护理的现成干细胞血管移植物
- 批准号:
10189694 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
相似国自然基金
巨噬细胞PIEZO1通过肌动蛋白骨架-线粒体自噬轴调控皮肤纤维化
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
NEXN突变抑制FMNL3介导的肌动蛋白聚合导致先天性冠状动脉畸形的机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
肌动蛋白ACTRT3缺陷造成精子受精障碍的机制研究
- 批准号:2025JJ50703
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
双相情感障碍风险基因TRANK1参与肌动蛋白结构重塑从而调节突触发育和可塑性及行为的作用和机制研究
- 批准号:2025JJ60220
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
法舒地尔通过CaMK4/Rho GTPases信号修复足细胞肌动蛋白骨架治疗狼疮性肾炎的机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于NPFs调控肌动蛋白成核因子Arp2/3复合物探讨微丝骨架动态在病理性心肌肥大中的机制
- 批准号:JCZRLH202501065
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
E3酶SCFFBXO44动态调控肌动蛋白丝易损性促胃癌进展的分子机制研究
- 批准号:QKHM25H3103
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
α辅肌动蛋白-4通过FTO介导的N6-甲基腺苷去甲基化修饰促进骨肉瘤肺转移的机制研究
- 批准号:2024Y9173
- 批准年份:2024
- 资助金额:15.0 万元
- 项目类别:省市级项目
糖基转移酶COLGALT1介导FSCN1糖基化调控肌动蛋白骨架重塑促进肝细胞癌转移的机制研究
- 批准号:2024Y9179
- 批准年份:2024
- 资助金额:15.0 万元
- 项目类别:省市级项目
基于破骨细胞骨架重组对肌动蛋白环的影响探讨肾虚在绝经后骨质疏松症发生中的作用
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
相似海外基金
A novel motility system driven by two classes of bacterial actins MreB
由两类细菌肌动蛋白 MreB 驱动的新型运动系统
- 批准号:
22KJ2613 - 财政年份:2023
- 资助金额:
$ 41.88万 - 项目类别:
Grant-in-Aid for JSPS Fellows
The structural basis of plasmid segregation by bacterial actins
细菌肌动蛋白分离质粒的结构基础
- 批准号:
342887 - 财政年份:2016
- 资助金额:
$ 41.88万 - 项目类别:
Operating Grants
The structural basis for plasmid segregation by bacterial actins
细菌肌动蛋白分离质粒的结构基础
- 批准号:
278338 - 财政年份:2013
- 资助金额:
$ 41.88万 - 项目类别:
Operating Grants
Cytoplasmic Actins in Maintenance of Muscle Mitochondria
细胞质肌动蛋白在维持肌肉线粒体中的作用
- 批准号:
8505938 - 财政年份:2012
- 资助金额:
$ 41.88万 - 项目类别:
Differential Expression of the Diverse Plant Actins
多种植物肌动蛋白的差异表达
- 批准号:
7931495 - 财政年份:2009
- 资助金额:
$ 41.88万 - 项目类别:
Studies on how actins and microtubules are coordinated and its relevancy.
研究肌动蛋白和微管如何协调及其相关性。
- 批准号:
19390048 - 财政年份:2007
- 资助金额:
$ 41.88万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Interaction of myosin with monomeric actins
肌球蛋白与单体肌动蛋白的相互作用
- 批准号:
5311554 - 财政年份:2001
- 资助金额:
$ 41.88万 - 项目类别:
Priority Programmes
STRUCTURE/INTERACTIONS OF ACTINS AND ACTIN-BINDING PROTEIN
肌动蛋白和肌动蛋白结合蛋白的结构/相互作用
- 批准号:
6316669 - 财政年份:2000
- 资助金额:
$ 41.88万 - 项目类别: